Editorial: Linking Overt Hepatic Encephalopathy Post-TIPS to Mortality!

IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Anjan Kumar, Margaret L. P. Teng, Anand V. Kulkarni
{"title":"Editorial: Linking Overt Hepatic Encephalopathy Post-TIPS to Mortality!","authors":"Anjan Kumar,&nbsp;Margaret L. P. Teng,&nbsp;Anand V. Kulkarni","doi":"10.1111/apt.70005","DOIUrl":null,"url":null,"abstract":"<p>Transjugular intrahepatic portosystemic shunt (TIPS) placement is an effective therapy for portal hypertension-related complications and has significant survival benefits for patients with recurrent/refractory ascites and variceal bleeding [<span>1</span>]. Although procedure-related mortality is low (&lt; 1%), common post-TIPS complications, which affect quality of life, include overt hepatic encephalopathy (OHE), decrease in liver function and cardiopulmonary dysfunction [<span>2</span>]. Around 30%–50% of patients develop an episode of HE post-TIPS, with 10% developing disabling HE requiring recurrent hospitalisations [<span>3, 4</span>]. However, the impact of post-TIPS OHE on mortality remains unclear.</p><p>Xiang et al. conducted a large multicentre retrospective cohort study comprising 3262 patients with cirrhosis underwent TIPS for variceal bleeding [<span>5</span>]. Post-TIPS OHE occurred in 33.2% of patients, of which 631 (19.3%) patients subsequently died. It was found that post-TIPS OHE independently predicted long-term mortality (beyond 24 months), but not short-term mortality within 6 months. Additionally, development of post-TIPS OHE within 1 month was associated with higher long-term mortality. The authors must be lauded for this exceptional long-term follow-up study, which provides invaluable insights into HE and mortality.</p><p>A recent multicentre prospective study by Nardelli et al. reported that <i>episodic</i> post-TIPS OHE was not associated with higher mortality [<span>6</span>]. However, the percentage of patients with <i>persistent</i> post-TIPS OHE was significantly higher among patients who died. It is worth noting that median follow-up in this study was 30 months, slightly less than the 1077 days (~35 months) in Yi's study. A subsequent meta-analysis of seven cohort studies comprising 1712 patients showed that post-TIPS HE was associated with increased risk of mortality [<span>7</span>]. Yi's observation is hence in line with current literature, and the large cohort size adds credence to the link between post-TIPS HE and mortality. Additionally, Hartl et al. supported the observation that early onset of post-TIPS OHE within 1 month was linked with higher mortality [<span>8</span>].</p><p>Short-term mortality post-TIPS is predominantly driven by liver function, portal hypertension and stent-related complications, thereby suggesting a lack of association between post-TIPS OHE and short-term mortality. Only history of ascites and diameter of TIPS stent were significantly associated with mortality at 6 months, which suggests that these patients had an existing significant degree of portal hypertension not fully correctable by TIPS. Furthermore, 43.4% of patients who died within 12 months had stent dysfunction, which may exacerbate portal hypertension-related complications.</p><p>The study has numerous limitations. First, a higher proportion of patients with OHE had variceal bleeding, which may have been the trigger for HE and mortality. The study did not report the severity scores, cardiopulmonary complications and prophylactic measures at various post-procedure time points, which could have been invaluable in identifying predictors of HE and mortality [<span>9</span>]. In addition, sarcopenia is a key factor, which could affect post-TIPS mortality, and was not accounted for in this study [<span>10</span>]. More granular data on post-TIPS OHE (time to development of HE, classification and severity) and association of these parameters with mortality will refine our understanding of the impact of post-TIPS OHE on mortality. Further studies are needed to assess the impact of prophylactic therapies in prevention of HE and develop biomarkers for prediction of HE pre-TIPS. (Table 1).</p><p><b>Anjan Kumar:</b> writing – original draft. <b>Margaret L. P. Teng:</b> writing – original draft. <b>Anand V. Kulkarni:</b> conceptualization, writing – review and editing.</p><p>The authors declare no conflicts of interest.</p><p>This article is linked to Xiang et al paper. To view this article, visit https://doi.org/10.1111/apt.18509</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"61 7","pages":"1238-1239"},"PeriodicalIF":6.6000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.70005","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apt.70005","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Transjugular intrahepatic portosystemic shunt (TIPS) placement is an effective therapy for portal hypertension-related complications and has significant survival benefits for patients with recurrent/refractory ascites and variceal bleeding [1]. Although procedure-related mortality is low (< 1%), common post-TIPS complications, which affect quality of life, include overt hepatic encephalopathy (OHE), decrease in liver function and cardiopulmonary dysfunction [2]. Around 30%–50% of patients develop an episode of HE post-TIPS, with 10% developing disabling HE requiring recurrent hospitalisations [3, 4]. However, the impact of post-TIPS OHE on mortality remains unclear.

Xiang et al. conducted a large multicentre retrospective cohort study comprising 3262 patients with cirrhosis underwent TIPS for variceal bleeding [5]. Post-TIPS OHE occurred in 33.2% of patients, of which 631 (19.3%) patients subsequently died. It was found that post-TIPS OHE independently predicted long-term mortality (beyond 24 months), but not short-term mortality within 6 months. Additionally, development of post-TIPS OHE within 1 month was associated with higher long-term mortality. The authors must be lauded for this exceptional long-term follow-up study, which provides invaluable insights into HE and mortality.

A recent multicentre prospective study by Nardelli et al. reported that episodic post-TIPS OHE was not associated with higher mortality [6]. However, the percentage of patients with persistent post-TIPS OHE was significantly higher among patients who died. It is worth noting that median follow-up in this study was 30 months, slightly less than the 1077 days (~35 months) in Yi's study. A subsequent meta-analysis of seven cohort studies comprising 1712 patients showed that post-TIPS HE was associated with increased risk of mortality [7]. Yi's observation is hence in line with current literature, and the large cohort size adds credence to the link between post-TIPS HE and mortality. Additionally, Hartl et al. supported the observation that early onset of post-TIPS OHE within 1 month was linked with higher mortality [8].

Short-term mortality post-TIPS is predominantly driven by liver function, portal hypertension and stent-related complications, thereby suggesting a lack of association between post-TIPS OHE and short-term mortality. Only history of ascites and diameter of TIPS stent were significantly associated with mortality at 6 months, which suggests that these patients had an existing significant degree of portal hypertension not fully correctable by TIPS. Furthermore, 43.4% of patients who died within 12 months had stent dysfunction, which may exacerbate portal hypertension-related complications.

The study has numerous limitations. First, a higher proportion of patients with OHE had variceal bleeding, which may have been the trigger for HE and mortality. The study did not report the severity scores, cardiopulmonary complications and prophylactic measures at various post-procedure time points, which could have been invaluable in identifying predictors of HE and mortality [9]. In addition, sarcopenia is a key factor, which could affect post-TIPS mortality, and was not accounted for in this study [10]. More granular data on post-TIPS OHE (time to development of HE, classification and severity) and association of these parameters with mortality will refine our understanding of the impact of post-TIPS OHE on mortality. Further studies are needed to assess the impact of prophylactic therapies in prevention of HE and develop biomarkers for prediction of HE pre-TIPS. (Table 1).

Anjan Kumar: writing – original draft. Margaret L. P. Teng: writing – original draft. Anand V. Kulkarni: conceptualization, writing – review and editing.

The authors declare no conflicts of interest.

This article is linked to Xiang et al paper. To view this article, visit https://doi.org/10.1111/apt.18509

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.60
自引率
7.90%
发文量
527
审稿时长
3-6 weeks
期刊介绍: Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信